Stroke is the third leading cause of death and the leading cause for long-term disability in the U.S. and other industrialized nations. Each year 750,000 Americans suffer, and more than 150,000 die as a result of new and recurrent strokes. In spite of extensive research efforts, to date only one drug, the thrombolytic agent tPA, has been approved by the FDA for stroke treatment. A number of alternative neuroprotective approaches have been identified in animal ischemia models, but failed in clinical trials. Therefore there is continuous need for development and improvement of novel stroke therapies. In this study we propose to test the novel HYPOTHESIS that oxidative stress potently augments and propagates ischemic brain damage by enhancing glial glutamate release via activation of redox-sensitive glutamate transport pathways. Studies from this and other laboratories has identified three redox-sensitive glutamate release pathways: volume-regulated anion channels (VRAC), the cystine/glutamate antiporter (xCT), and the connexin hemichannels (Cxs). In the proposed work we will use pure and mixed primary cultures of rat astrocytes and microglial cells to find the optimal approaches for reducing pathological glutamate release from glia. This will be followed by testing novel pharmacological treatments in vivo, in a rat model of transient focal ischemia. The following SPECIFIC AIMS are proposed:
(AIM 1) to elucidate relative contribution of VRAC, xCT, and Cxs to glutamate release in response to oxidative stress in primary glial cultures, using pharmacological tools and an siRNA approach;
(AIM 2) to identify the relationship between oxidative stress and pathological glutamate release in vivo in a rat model of transient focal ischemia, using a microdialysis approach and the intra-dialysate drug delivery;
(AIM 3) to test the neuroprotective potential of the pharmacological treatments validated in AIMS 1 and 2, by measuring brain infarction volumes in the control ischemia group and after treatment with neuroprotectants. The major objective of this study is to establish a new fundamental relationship between tissue production of reactive oxygen species and pathological glutamate release from glial cells, and to identify novel pharmacological targets in stroke and other neurological disorders (such as multiple sclerosis, Alzheimer's disease, and traumatic brain injury), which involve oxidative stress.

Public Health Relevance

Stroke is a devastating brain disorder that affects 750,000 Americans every year, killing more than 150,000 people and leaving many others permanently debilitated. Presently, only one pharmacological agent, tissue plasminogen activator (tPA), has been approved for acute stroke treatment. Because of several clinical limitations, tPA is used in only 5 to 8% of stroke patients. The present project will study previously unrecognized mechanisms of brain damage and seek to develop new pharmacological agents for stroke treatment.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS061953-05
Application #
8512810
Study Section
Brain Injury and Neurovascular Pathologies Study Section (BINP)
Program Officer
Bosetti, Francesca
Project Start
2009-08-05
Project End
2014-07-31
Budget Start
2013-08-01
Budget End
2014-07-31
Support Year
5
Fiscal Year
2013
Total Cost
$333,863
Indirect Cost
$122,557
Name
Albany Medical College
Department
Pharmacology
Type
Schools of Medicine
DUNS #
190592162
City
Albany
State
NY
Country
United States
Zip Code
12208
Dohare, Preeti; Hyzinski-García, María C; Vipani, Aarshi et al. (2014) The neuroprotective properties of the superoxide dismutase mimetic tempol correlate with its ability to reduce pathological glutamate release in a rodent model of stroke. Free Radic Biol Med 77:168-82
Kuo, Yu-Hung; Abdullaev, Iskandar F; Hyzinski-Garcia, Maria C et al. (2014) Effects of alternative splicing on the function of bestrophin-1 calcium-activated chloride channels. Biochem J 458:575-83
Hyzinski-García, María C; Rudkouskaya, Alena; Mongin, Alexander A (2014) LRRC8A protein is indispensable for swelling-activated and ATP-induced release of excitatory amino acids in rat astrocytes. J Physiol 592:4855-62
Zuidema, Jonathan M; Hyzinski-Garcia, Maria C; Van Vlasselaer, Kristien et al. (2014) Enhanced GLT-1 mediated glutamate uptake and migration of primary astrocytes directed by fibronectin-coated electrospun poly-L-lactic acid fibers. Biomaterials 35:1439-49
Motiani, Rajender K; Hyzinski-Garcia, Maria C; Zhang, Xuexin et al. (2013) STIM1 and Orai1 mediate CRAC channel activity and are essential for human glioblastoma invasion. Pflugers Arch 465:1249-60
Bowens, Nicole H; Dohare, Preeti; Kuo, Yu-Hung et al. (2013) DCPIB, the proposed selective blocker of volume-regulated anion channels, inhibits several glutamate transport pathways in glial cells. Mol Pharmacol 83:22-32
Agarwal, Jay J; Zhu, Yi; Zhang, Qing-Yu et al. (2013) TRAM-34, a putatively selective blocker of intermediate-conductance, calcium-activated potassium channels, inhibits cytochrome P450 activity. PLoS One 8:e63028
Mongin, Alexander A (2013) Potential link between cysteinyl-leukotriene receptors and release of bioactive amino acids in regulation of lung function. Focus on "Volume-sensitive release of organic osmolytes in the human lung epithelial cell line A549: role of the 5-lipoxygenase". Am J Physiol Cell Physiol 305:C24-5
Mongin, Alexander A; Dohare, Preeti; Jourd'heuil, David (2012) Selective vulnerability of synaptic signaling and metabolism to nitrosative stress. Antioxid Redox Signal 17:992-1012
Koltsova, Svetlana V; Platonova, Alexandra; Maksimov, Georgy V et al. (2011) Activation of P2Y receptors causes strong and persistent shrinkage of C11-MDCK renal epithelial cells. Am J Physiol Cell Physiol 301:C403-12

Showing the most recent 10 out of 13 publications